Kardigan Reports $116.2 Million Net Loss and Completes IPO Raising $422.4 Million

Kardigan, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $116.2 million for the quarter, compared to a loss of $57.4 million in the same period last year, marking a 102% increase in losses. Total operating expenses surged to $118.8 million, up from $57.1 million in the prior year, driven primarily by a 57% increase in research and development expenses, which reached $56.4 million. This increase reflects the company's ongoing clinical activities, particularly the advancement of its late-stage programs, including Danicamtiv, Ataciguat, and Tonlamarsen.

In terms of liquidity, Kardigan completed its initial public offering (IPO) on June 22, 2026, raising approximately $422.4 million in net proceeds after deducting underwriting costs. As of June 30, 2026, the company reported cash, cash equivalents, and investments totaling $660.7 million, a substantial increase from $108.9 million at the end of 2025. This capital is expected to support the company's operations for at least the next twelve months, as it continues to invest in its research and development initiatives.

Kardigan's operational metrics indicate a strategic focus on expanding its clinical trials and product development. The company has initiated the KARDINAL-ASH Phase 2 clinical trial for Tonlamarsen and completed enrollment for the KINSHIP-DCM trial for Danicamtiv. The company anticipates reporting clinical data from these trials in the first half of 2027. Additionally, the filing noted a significant increase in the fair value of contingent milestone liabilities, which rose to $47.3 million as of June 30, 2026, reflecting the company's enhanced market valuation following its IPO.

The company has also made strategic acquisitions, including Prolaio, Inc., which has provided access to a cardiovascular data platform to enhance its research capabilities. The acquisition included contingent milestone payments of up to $200 million, contingent on achieving specific operational and financial milestones. Kardigan's management emphasized the importance of these developments in positioning the company for future growth in the competitive biopharmaceutical landscape.

Looking ahead, Kardigan expects to continue incurring substantial operating losses as it advances its clinical programs and seeks regulatory approvals. The company remains focused on its mission to develop targeted therapies for cardiovascular diseases, aiming to bring three high-impact medicines to pivotal studies within a four-year timeframe, subject to regulatory approval.